Moderna (MRNA) Akcija Цена

Moderna Цена

NYSE·ZATVORENO
254,19
​
Tržište je zatvoreno

Prihod je rastao 112,0 % godišnje u poslednjih 11 godina na 1,94 Млрд USD. neto marža kompanije Moderna sada iznosi -145,2 %, pala sa 68,8 % pre nekoliko godina. Medijana analitičke ciljane cene je 63,81 USD, odnosno ispod trenutnu cenu za 74,9 %. Od 32 analitičara 13 preporučuje kupovinu — ukupni konsenzus je Drži.

Cena akcije Moderna

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Moderna poslovni model i analiza akcije

Moderna Inc je biotehnološka kompanija iz SAD-a koja se specijalizovala za razvoj terapija i vakcina zasnovanih na mRNA tehnologiji. Kompaniju je 2010. godine osnovala grupa istraživača predvođena Noubarom Afeyanom, a sedište joj se nalazi u Kembridžu, Masačusets.

Često postavljana pitanja o akciji Moderna

Moderna Inc is a biotechnology company with a business model that focuses on the development and commercialization of mRNA-based therapeutics and vaccines. The company utilizes mRNA technology to create personalized medicine and improve healthcare outcomes. With an emphasis on infectious diseases, rare diseases, and oncology, Moderna Inc leverages its platform to develop a diverse pipeline of innovative treatments. By harnessing the potential of mRNA, Moderna Inc aims to revolutionize the way diseases are prevented and treated, offering new hope and possibilities for patients globally.

Moderna Inc is primarily active in the biotechnology and pharmaceutical industries.

Moderna Inc faces competition from various companies in the market, including established pharmaceutical giants such as Pfizer, Johnson & Johnson, and AstraZeneca. These competitors also focus on developing and distributing vaccines and therapeutics, much like Moderna Inc. However, Moderna Inc stands out for its pioneering messenger RNA (mRNA) technology, which has gained significant attention and recognition. With its innovative approach and potential for addressing unmet medical needs, Moderna Inc continues to position itself as a prominent player in the biopharmaceutical industry and compete against other industry leaders in the market.

Moderna Inc, a leading biotechnology company, was founded in 2010. Headquartered in Cambridge, Massachusetts, Moderna specializes in the development of mRNA-based medicines and therapies. By utilizing the potential of messenger RNA (mRNA) technology, the company aims to revolutionize the field of medicine. Moderna has a diverse pipeline of investigational programs, targeting various diseases, including infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. The company's commitment to innovation and cutting-edge research has attracted strategic collaborations with renowned organizations and industry leaders. With its groundbreaking approach and promising advancements, Moderna Inc continues to make significant contributions to the biomedical field.

Moderna Inc, a renowned biotechnology company, has achieved several significant milestones. Notably, Moderna became the first company to release an mRNA-based vaccine authorized for emergency use against COVID-19, known as the Moderna COVID-19 Vaccine. This breakthrough marked a monumental achievement in the fight against the global pandemic. Additionally, Moderna has made remarkable progress in advancing mRNA-based therapies for various diseases, including cancer and rare genetic disorders. Through strategic collaborations and cutting-edge research, Moderna has demonstrated its commitment to revolutionize medicine by harnessing the power of mRNA technology. Moderna Inc's dedication to innovation and groundbreaking achievements position it as a leading player in the biotech industry.

Moderna Inc is primarily present in several countries and regions worldwide. The company has its headquarters in Cambridge, Massachusetts, United States. Apart from the US, Moderna Inc has a notable presence in various countries and regions such as Europe, including the United Kingdom, Germany, France, and Switzerland. Additionally, Moderna Inc operates in Asia, with a presence in Japan and South Korea. The company also has collaborations and partnerships with organizations and institutions globally, enabling its presence in diverse regions for the development and distribution of its innovative mRNA-based vaccines and therapies.

Moderna Inc represents a commitment to pioneering transformative medicines based on messenger RNA (mRNA) technology. The company's corporate philosophy centers around innovation, collaboration, and patient-focused progress. Moderna believes in leveraging its proprietary mRNA platform to develop a vast range of potential therapeutics and vaccines to tackle various diseases. The company strives to address unmet medical needs and improve global healthcare through its cutting-edge research and development efforts. Moderna's dedication to scientific excellence, forward-thinking strategies, and ongoing partnerships positions it as a leader in the biotechnology industry, driving breakthroughs and shaping the future of medicine.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 77,99 USD za akciju Moderna (medijana: 63,81 USD), što znači -69,3 % u odnosu na poslednju cenu. Konsenzus se zasniva na 32 ocena.

31 analitičara trenutno ocenjuje akciju Moderna: 10 preporučuje kupovinu, 17 držanje i 4 prodaju. Za 2026 analitičari očekuju da Moderna ostvari prihod 2,10 Млрд USD i zaradu po akciji -8,39 USD.

Po trenutnom kursu akcija Moderna kotira 227,78 EUR (254,19 USD).

Akcija Moderna (MRNA) kotira na 13 berze, uključujući: NYSE (MRNA), London (0A45.L), SIX (Zürich) (0QF.SW), XETRA (0QF.DE), Frankfurt (0QF.F), München (0QF.MU), Stuttgart (0QF.SG), Düsseldorf (0QF.DU).

Moderna Inc is a biotechnology company focused on the development and production of mRNA therapeutics and vaccines. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts, USA. The core divisions of Moderna Inc include research and development, production, and marketing of mRNA-based therapeutics and vaccines. In the field of research and development, Moderna Inc is working to discover and develop new therapies and vaccines for a variety of diseases. The company has a broad range of therapy areas such as immuno-oncology, infectious diseases, rare diseases, autoimmune diseases, and cardiovascular diseases. Moderna Inc's product line includes mRNA-based therapeutics and vaccines. The company has already conducted several clinical trials in various therapy areas, including cancer, heart attack, and influenza. The company has also developed and produced vaccines against COVID-19, which have already been approved by many countries and used by millions of people worldwide. Moderna Inc also operates a production facility in Massachusetts, USA. The company has a proven ability to rapidly and on a large scale produce mRNA-based products, enabling it to quickly respond to epidemics and pandemics, as was the case with the COVID-19 pandemic. Moderna Inc's business model is based on the commercialization of mRNA-based therapeutics and vaccines. The company leverages its advanced technology and state-of-the-art production processes to develop fast and effective solutions for fighting diseases. The company has also formed partnerships with other companies, government agencies, and universities around the world to share and expand its technology and expertise. Moderna Inc is a publicly traded company listed on the Nasdaq stock exchange in the USA. The company has a strong financial structure and has a wide range of investors and partners worldwide. Overall, Moderna Inc has an innovative and promising business model. By developing and producing mRNA-based products, the company is contributing to fighting a wide range of diseases and improving the well-being of people worldwide. With its strong market position and advanced technology, the company is well-positioned to continue growing and succeeding in the future.

očekivana prihod od Moderna je 2,10 Млрд USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od Moderna je -3,29 Млрд USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Moderna je trenutno -30,30. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Moderna.

Odnos cene i prihoda (KUV) za Moderna je trenutno 47,43. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju Moderna.

Eulpool score kvaliteta za Moderna je 2/10.

ISIN za Moderna je US60770K1079. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Moderna je A2N9D9. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Moderna je MRNA. Simbol tikera se koristi za trgovinu akcijama Moderna na berzanskom tržištu.

Фер вредностTerminal
246,56 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Биотехнологија
Број акција
Запослени
Приход по запосленом
413.617,02 USD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт modernatx.com
Валута
USD
Јавна понуда
7. дец 2018.
ISIN
US60770K1079
CUSIP
60770K107
SEDOL
BGSXTS3
Тржишна капитализација
Опсег од 52 недеље
AAQS
2 / 10
PEG
—
P/E однос
P/Ee 2026
-30,30
P/Ee 2027
-53,64
P/Ee 2028
-89,50
P/Ee 2029
714,96
P/Ee 2030
72,19
P/Se
47,43
EV/EBIT
—
P/B однос
11,48
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
-30,48 %
Zadnje ažurirano 7. нов 2026. 17:40

Moderna Тикер

BERLIN · 0QF.BEDISELORF · 0QF.DUFRANKFURT · 0QF.FHAMBURG · 0QF.HMLONDON · 0A45.LMILAN · 1MRNA.MIMINHEN · 0QF.MUNASDAQ · MRNANEW YORK · MRNASIX · 0QF.SWŠTUTGART · 0QF.SGBEČ · MRNA.VI

Moderna FIGI

MRNA:US · BBG003PHHZT1MRNA:UA · BBG00MJW66D6MRNA:UC · BBG00MJW66F4MRNA:UN · BBG00MJW66H2MRNA:UP · BBG00MJW66J0MRNA:UB · BBG00MJW66L7MRNA:UM · BBG00MJW66N5MRNA:UX · BBG00MJW66P3MRNA:UD · BBG00MJW66V6MRNA:UW · BBG00MJW66X4MRNA:UF · BBG00MJW66Y3MRNA:VY · BBG00MJW66Z2

Sve ključne metrke i detaljne analize Moderna u dubinskoj analizi

Naša analiza akcija za akciju Moderna uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Moderna. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: